The DOE Joint Genome Institute conducted an extensive internal product audit to analyze the scientific value, demand, and costs of current offerings in the JGI product catalog. The resulting information is being used to prioritize products for potential future expansion or elimination. A detailed summary of the findings revealed a set of JGI products of low scientific impact and low demand, yet high cost and extensive labor requirements. The JGI will discontinue these products.
The JGI will no longer offer smRNA, bisulfite, or ChIP sequencing, beginning with FY23 proposals. Eliminating these products creates an opportunity to redirect resources toward making new and potentially more impactful capabilities aligned with the DOE mission available to the JGI user community.
The JGI will honor existing commitments – e.g., smRNA, bisulfite, or ChIP sequencing requests – that are part of approved JGI proposals. The relevant Project Manager will contact those whose proposals entail these requests to discuss sample availability and estimated shipping schedules.